.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,265,725

« Back to Dashboard
Patent 9,265,725 protects FINACEA and is included in one NDA. There has been one Paragraph IV challenge on Finacea. There is one tentative approval for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has one hundred and thirty-two patent family members in eighteen countries.

Summary for Patent: 9,265,725

Title:Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
Abstract: The present invention teaches a foamable pharmaceutical carrier comprising a benefit agent, selected from the group consisting of a dicarboxylic acid and a dicarboxylic acid ester; a stabilizer selected from the group consisting of at least one surface-active agent; at least one polymeric agent and mixtures thereof; a solvent selected from the group consisting of water, a hydrophilic solvent, a hydrophobic solvent, a potent solvent, a polar solvent, a silicone, an emollient, and mixtures thereof, wherein the benefit agent, stabilizer and solvent are selected to provide a composition that is substantially resistant to aging and to phase separation and or can substantially stabilize other active ingredients. The invention further relates to a foamable composition further containing a liquefied hydrocarbon gas propellant.
Inventor(s): Tamarkin; Dov (Maccabim, IL), Friedman; Doron (Karmei Yosef, IL), Berman; Tal (Rishon LeZiyyon, IL), Ziv; Enbal (Gedera, IL), Schuz; David (Moshav Gimzu, IL)
Assignee: Foamix Pharmaceuticals Ltd. (Rehovot, IL)
Application Number:11/825,406
Patent Claim Types:
see list of patent claims
Composition; Compound;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 939th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Bayer Hlthcare
FINACEA
azelaic acid
AEROSOL, FOAM;TOPICAL207071-001Jul 29, 2015RXYes9,265,725► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 9,265,725

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Israel152486Oct 25, 2002

Non-Orange Book Patents for Patent: 9,265,725

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,518,378Oleaginous pharmaceutical and cosmetic foam► subscribe
8,741,265Penetrating pharmaceutical foam► subscribe
8,722,021Foamable carriers► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,265,725

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO)2007072216► subscribe
Israel152486► subscribe
Israel168399► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc